, SUZHOU, China and HANGZHOU, China
, Jan. 6, 2020
/PRNewswire/ -- Transcenta Holding (Transcenta) today announced that Co-founder & CEO Dr. Xueming Qian
will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020
, at 14:30 PST
in Golden Gate room at Westin St. Francis, San Francisco
. Dr. Xueming Qian
will share the company's latest development and clinical progresses made to the audience and potential investors.
Merged by MabSpace and HJB in January
2019, Transcenta is a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacturing. In the past year, Transcenta has made significant progresses, e.g. it has built a complimentary team with extensive global industrial experience with the addition of multiple seasoned clinical development leaders, assembled a robust pipeline with over 10 innovative molecules in oncology, bone disorders, nephrology, in-licensed a phase 2 completed anti-sclerostin therapeutic program Blosozumab for severe osteoporosis, and adopted integrated continuous process and manufacturing in its Hangzhou
facility to achieve low cost of goods.
About Transcenta Holding Limited
Transcenta is a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacturing. With Discovery and Translational Research Center in Suzhou, Process and Product Development Center and Manufacturing Facility in Hangzhou
, and Clinical Development Centers in Shanghai
and in Princeton
, US, and External Partnering Center in Boston
, US, Transcenta has established global footprint. Currently, Transcenta has over 10 innovative oncology and select non-oncology molecules in its pipeline. www.transcenta.com.
For more information, please contact:firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/transcenta-to-present-at-the-38th-annual-jp-morgan-healthcare-conference-300981465.html
SOURCE Transcenta Holding